{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,21]],"date-time":"2026-11-21T08:42:17Z","timestamp":1795250537722,"version":"4.10.3"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,1,31]],"date-time":"2019-01-31T00:00:00Z","timestamp":1548892800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s13058-019-1098-z","type":"journal-article","created":{"date-parts":[[2019,1,31]],"date-time":"2019-01-31T09:03:48Z","timestamp":1548925428000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["A subgroup of microRNAs defines PTEN-deficient, triple-negative breast cancer patients with poorest prognosis and alterations in RB1, MYC, and Wnt signaling"],"prefix":"10.1186","volume":"21","author":[{"given":"Dong-Yu","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deena M. A.","family":"Gendoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaacov","family":"Ben-David","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James R.","family":"Woodgett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eldad","family":"Zacksenhaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,1,31]]},"reference":[{"issue":"1","key":"1098_CR1","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.molonc.2010.11.003","volume":"5","author":"A Prat","year":"2011","unstructured":"Prat A, Perou CM. Deconstructing the molecular portraits of breast cancer. Mol Oncol. 2011;5(1):5\u201323.","journal-title":"Mol Oncol"},{"issue":"22","key":"1098_CR2","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","volume":"379","author":"P Schmid","year":"2018","unstructured":"Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, Dieras V, Hegg R, Im SA, Shaw Wright G, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018;379(22):2108\u201321.","journal-title":"N Engl J Med"},{"issue":"7","key":"1098_CR3","doi-asserted-by":"publisher","first-page":"2750","DOI":"10.1172\/JCI45014","volume":"121","author":"BD Lehmann","year":"2011","unstructured":"Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, Pietenpol JA. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121(7):2750\u201367.","journal-title":"J Clin Invest"},{"issue":"8","key":"1098_CR4","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.18632\/oncotarget.1170","volume":"4","author":"JC Liu","year":"2013","unstructured":"Liu JC, Egan SE, Zacksenhaus E. A tumor initiating cell-enriched prognostic signature for HER2+:ERalpha- breast cancer; rationale, new features, controversies and future directions. Oncotarget. 2013;4(8):1317\u201328.","journal-title":"Oncotarget"},{"issue":"7449","key":"1098_CR5","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1038\/nature12108","volume":"497","author":"H Dvinge","year":"2013","unstructured":"Dvinge H, Git A, Graf S, Salmon-Divon M, Curtis C, Sottoriva A, Zhao Y, Hirst M, Armisen J, Miska EA, et al. The shaping and functional consequences of the microRNA landscape in breast cancer. Nature. 2013;497(7449):378\u201382.","journal-title":"Nature"},{"key":"1098_CR6","doi-asserted-by":"publisher","first-page":"15004","DOI":"10.1038\/sigtrans.2015.4","volume":"1","author":"Y Peng","year":"2016","unstructured":"Peng Y, Croce CM. The role of microRNAs in human cancer. Signal Transduct Target Ther. 2016;1:15004.","journal-title":"Signal Transduct Target Ther"},{"issue":"10","key":"1098_CR7","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1038\/aps.2015.67","volume":"36","author":"MH Li","year":"2015","unstructured":"Li MH, Fu SB, Xiao HS. Genome-wide analysis of microRNA and mRNA expression signatures in cancer. Acta Pharmacol Sin. 2015;36(10):1200\u201311.","journal-title":"Acta Pharmacol Sin"},{"issue":"7403","key":"1098_CR8","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/nature10983","volume":"486","author":"C Curtis","year":"2012","unstructured":"Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, Speed D, Lynch AG, Samarajiwa S, Yuan Y, et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature. 2012;486(7403):346\u201352.","journal-title":"Nature"},{"key":"1098_CR9","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/nature11412","volume":"490","author":"DC Koboldt","year":"2012","unstructured":"Koboldt DC, Fulton RS, McLellan MD, Schmidt H, Kalicki-Veizer J, McMichael JF, Fulton LL, Dooling DJ, Ding L, Mardis ER, et al. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490:61\u201370.","journal-title":"Nature"},{"issue":"7605","key":"1098_CR10","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nature17676","volume":"534","author":"S Nik-Zainal","year":"2016","unstructured":"Nik-Zainal S, Davies H, Staaf J, Ramakrishna M, Glodzik D, Zou X, Martincorena I, Alexandrov LB, Martin S, Wedge DC, et al. Landscape of somatic mutations in 560 breast cancer whole-genome sequences. Nature. 2016;534(7605):47\u201354.","journal-title":"Nature"},{"issue":"7667","key":"1098_CR11","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1038\/nature23306","volume":"548","author":"DR Robinson","year":"2017","unstructured":"Robinson DR, Wu YM, Lonigro RJ, Vats P, Cobain E, Everett J, Cao X, Rabban E, Kumar-Sinha C, Raymond V, et al. Integrative clinical genomics of metastatic cancer. Nature. 2017;548(7667):297\u2013303.","journal-title":"Nature"},{"key":"1098_CR12","doi-asserted-by":"crossref","unstructured":"Wang S, Liu JC, Ju Y, Pellecchia G, Voisin V, Wang DY, Leha LR, Ben-David Y, Bader GD, Zacksenhaus E. microRNA-143\/145 loss induces Ras signaling to promote aggressive Pten-deficient basal-like breast cancer. JCI Insight. 2017;2(15):e93313.","DOI":"10.1172\/jci.insight.93313"},{"issue":"5","key":"1098_CR13","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1016\/j.molcel.2014.01.029","volume":"53","author":"E Vire","year":"2014","unstructured":"Vire E, Curtis C, Davalos V, Git A, Robson S, Villanueva A, Vidal A, Barbieri I, Aparicio S, Esteller M, et al. The breast cancer oncogene EMSY represses transcription of antimetastatic microRNA miR-31. Mol Cell. 2014;53(5):806\u201318.","journal-title":"Mol Cell"},{"issue":"17","key":"1098_CR14","doi-asserted-by":"publisher","first-page":"5635","DOI":"10.1158\/0008-5472.CAN-11-0489","volume":"71","author":"FM Buffa","year":"2011","unstructured":"Buffa FM, Camps C, Winchester L, Snell CE, Gee HE, Sheldon H, Taylor M, Harris AL, Ragoussis J. microRNA-associated progression pathways and potential therapeutic targets identified by integrated mRNA and microRNA expression profiling in breast cancer. Cancer Res. 2011;71(17):5635\u201345.","journal-title":"Cancer Res"},{"key":"1098_CR15","doi-asserted-by":"publisher","first-page":"11479","DOI":"10.1038\/ncomms11479","volume":"7","author":"B Pereira","year":"2016","unstructured":"Pereira B, Chin SF, Rueda OM, Vollan HKM, Provenzano E, Bardwell HA, Pugh M, Jones L, Russell R, Sammut SJ, et al. The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes. Nat Commun. 2016;7:11479.","journal-title":"Nat Commun"},{"issue":"15","key":"1098_CR16","doi-asserted-by":"publisher","first-page":"6994","DOI":"10.1073\/pnas.0912708107","volume":"107","author":"ML Gatza","year":"2010","unstructured":"Gatza ML, Lucas JE, Barry WT, Kim JW, Wang Q, Crawford MB, Datto MB, Kelley M, Mathey-Prevot B, Potti A, et al. A pathway-based classification of human breast cancer. Proc Natl Acad Sci. 2010;107(15):6994\u20139.","journal-title":"Proc Natl Acad Sci"},{"issue":"5","key":"1098_CR17","doi-asserted-by":"publisher","first-page":"R76","DOI":"10.1186\/gb-2007-8-5-r76","volume":"8","author":"JI Herschkowitz","year":"2007","unstructured":"Herschkowitz JI, Simin K, Weigman VJ, Mikaelian I, Usary J, Hu Z, Rasmussen KE, Jones LP, Assefnia S, Chandrasekharan S, et al. Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol. 2007;8(5):R76.","journal-title":"Genome Biol"},{"issue":"7","key":"1098_CR18","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, Smyth GK. Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47.","journal-title":"Nucleic Acids Res"},{"issue":"8","key":"1098_CR19","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1093\/bioinformatics\/btv723","volume":"32","author":"P Smirnov","year":"2016","unstructured":"Smirnov P, Safikhani Z, El-Hachem N, Wang D, She A, Olsen C, Freeman M, Selby H, Gendoo DM, Grossmann P, et al. PharmacoGx: an R package for analysis of large pharmacogenomic datasets. Bioinformatics. 2016;32(8):1244\u20136.","journal-title":"Bioinformatics"},{"issue":"12","key":"1098_CR20","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.15252\/emmm.201404402","volume":"6","author":"JC Liu","year":"2014","unstructured":"Liu JC, Voisin V, Wang S, Wang DY, Jones RA, Datti A, Uehling D, Al-awar R, Egan SE, Bader GD, et al. Combined deletion of Pten and p53 in mammary epithelium accelerates triple-negative breast cancer with dependency on eEF2K. EMBO Mol Med. 2014;6(12):1542\u201360.","journal-title":"EMBO Mol Med"},{"issue":"7403","key":"1098_CR21","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/nature11143","volume":"486","author":"MJ Ellis","year":"2012","unstructured":"Ellis MJ, Ding L, Shen D, Luo J, Suman VJ, Wallis JW, Van Tine BA, Hoog J, Goiffon RJ, Goldstein TC, et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature. 2012;486(7403):353\u201360.","journal-title":"Nature"},{"issue":"7403","key":"1098_CR22","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1038\/nature10933","volume":"486","author":"SP Shah","year":"2012","unstructured":"Shah SP, Roth A, Goya R, Oloumi A, Ha G, Zhao Y, Turashvili G, Ding J, Tse K, Haffari G, et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature. 2012;486(7403):395\u20139.","journal-title":"Nature"},{"issue":"7403","key":"1098_CR23","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1038\/nature11017","volume":"486","author":"PJ Stephens","year":"2012","unstructured":"Stephens PJ, Tarpey PS, Davies H, Van Loo P, Greenman C, Wedge DC, Nik-Zainal S, Martin S, Varela I, Bignell GR, et al. The landscape of cancer genes and mutational processes in breast cancer. Nature. 2012;486(7403):400\u20134.","journal-title":"Nature"},{"issue":"7484","key":"1098_CR24","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nature12912","volume":"505","author":"MS Lawrence","year":"2014","unstructured":"Lawrence MS, Stojanov P, Mermel CH, Robinson JT, Garraway LA, Golub TR, Meyerson M, Gabriel SB, Lander ES, Getz G. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature. 2014;505(7484):495\u2013501.","journal-title":"Nature"},{"issue":"10","key":"1098_CR25","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.4161\/cc.10.10.15703","volume":"10","author":"Z Jiang","year":"2011","unstructured":"Jiang Z, Jones R, Liu JC, Deng T, Robinson T, Chung PE, Wang S, Herschkowitz JI, Egan SE, Perou CM, et al. RB1 and p53 at the crossroad of EMT and triple-negative breast cancer. Cell Cycle. 2011;10(10):1563\u201370.","journal-title":"Cell Cycle"},{"issue":"1","key":"1098_CR26","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.celrep.2018.03.039","volume":"23","author":"JC Liu","year":"2018","unstructured":"Liu JC, Granieri L, Shrestha M, Wang DY, Vorobieva I, Rubie EA, Jones R, Ju Y, Pellecchia G, Jiang Z, et al. Identification of CDC25 as a common therapeutic target for triple-negative breast cancer. Cell Rep. 2018;23(1):112\u201326.","journal-title":"Cell Rep"},{"key":"1098_CR27","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.gene.2017.07.031","volume":"628","author":"Q Yuan","year":"2017","unstructured":"Yuan Q, Cao G, Li J, Zhang Y, Yang W. MicroRNA-136 inhibits colon cancer cell proliferation and invasion through targeting liver receptor homolog-1\/Wnt signaling. Gene. 2017;628:48\u201355.","journal-title":"Gene"},{"issue":"4","key":"1098_CR28","first-page":"1977","volume":"9","author":"J Huan","year":"2017","unstructured":"Huan J, Xing L, Lin Q, Xui H, Qin X. Long noncoding RNA CRNDE activates Wnt\/beta-catenin signaling pathway through acting as a molecular sponge of microRNA-136 in human breast cancer. Am J Transl Res. 2017;9(4):1977\u201389.","journal-title":"Am J Transl Res"},{"issue":"8","key":"1098_CR29","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1038\/nmeth.3485","volume":"12","author":"H Dweep","year":"2015","unstructured":"Dweep H, Gretz N. miRWalk2.0: a comprehensive atlas of microRNA-target interactions. Nat Methods. 2015;12(8):697.","journal-title":"Nat Methods"},{"issue":"15","key":"1098_CR30","doi-asserted-by":"publisher","first-page":"6994","DOI":"10.1073\/pnas.0912708107","volume":"107","author":"ML Gatza","year":"2010","unstructured":"Gatza ML, Lucas JE, Barry WT, Kim JW, Wang Q, Crawford MD, Datto MB, Kelley M, Mathey-Prevot B, Potti A, et al. A pathway-based classification of human breast cancer. Proc Natl Acad Sci U S A. 2010;107(15):6994\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5795","key":"1098_CR31","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1126\/science.1132939","volume":"313","author":"J Lamb","year":"2006","unstructured":"Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel MJ, Lerner J, Brunet JP, Subramanian A, Ross KN, et al. The connectivity map: using gene-expression signatures to connect small molecules, genes, and disease. Science. 2006;313(5795):1929\u201335.","journal-title":"Science"},{"issue":"11","key":"1098_CR32","doi-asserted-by":"publisher","first-page":"3057","DOI":"10.1158\/0008-5472.CAN-17-0096","volume":"77","author":"N El-Hachem","year":"2017","unstructured":"El-Hachem N, Gendoo DMA, Ghoraie LS, Safikhani Z, Smirnov P, Chung C, Deng K, Fang A, Birkwood E, Ho C, et al. Integrative cancer pharmacogenomics to infer large-scale drug taxonomy. Cancer Res. 2017;77(11):3057\u201369.","journal-title":"Cancer Res"},{"key":"1098_CR33","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.canlet.2016.11.033","volume":"388","author":"CW Lu","year":"2017","unstructured":"Lu CW, Lo YH, Chen CH, Lin CY, Tsai CH, Chen PJ, Yang YF, Wang CH, Tan CH, Hou MF, et al. VLDL and LDL, but not HDL, promote breast cancer cell proliferation, metastasis and angiogenesis. Cancer Lett. 2017;388:130\u20138.","journal-title":"Cancer Lett"},{"issue":"6","key":"1098_CR34","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.3892\/ol.2014.2014","volume":"7","author":"T Sui","year":"2014","unstructured":"Sui T, Ma L, Bai X, Li Q, Xu X. Resveratrol inhibits the phosphatidylinositide 3-kinase\/protein kinase B\/mammalian target of rapamycin signaling pathway in the human chronic myeloid leukemia K562 cell line. Oncol Lett. 2014;7(6):2093\u20138.","journal-title":"Oncol Lett"},{"issue":"16","key":"1098_CR35","doi-asserted-by":"publisher","first-page":"4477","DOI":"10.1158\/1078-0432.CCR-12-3401","volume":"19","author":"M Chan","year":"2013","unstructured":"Chan M, Liaw CS, Ji SM, Tan HH, Wong CY, Thike AA, Tan PH, Ho GH, Lee AS. Identification of circulating microRNA signatures for breast cancer detection. Clin Cancer Res. 2013;19(16):4477\u201387.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"1098_CR36","doi-asserted-by":"publisher","first-page":"3552","DOI":"10.1158\/0008-5472.CAN-10-2435","volume":"71","author":"Y Zhang","year":"2011","unstructured":"Zhang Y, Yan LX, Wu QN, Du ZM, Chen J, Liao DZ, Huang MY, Hou JH, Wu QL, Zeng MS, et al. miR-125b is methylated and functions as a tumor suppressor by regulating the ETS1 proto-oncogene in human invasive breast cancer. Cancer Res. 2011;71(10):3552\u201362.","journal-title":"Cancer Res"},{"key":"1098_CR37","first-page":"1231","volume":"9","author":"X He","year":"2016","unstructured":"He X, Wei Y, Wang Y, Liu L, Wang W, Li N. MiR-381 functions as a tumor suppressor in colorectal cancer by targeting Twist1. Onco Targets Ther. 2016;9:1231\u20139.","journal-title":"Onco Targets Ther"},{"issue":"3","key":"1098_CR38","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.ccr.2014.01.021","volume":"25","author":"PA Muller","year":"2014","unstructured":"Muller PA, Vousden KH. Mutant p53 in cancer: new functions and therapeutic opportunities. Cancer Cell. 2014;25(3):304\u201317.","journal-title":"Cancer Cell"},{"issue":"27","key":"1098_CR39","doi-asserted-by":"publisher","first-page":"3514","DOI":"10.1038\/onc.2014.279","volume":"34","author":"J Dembowy","year":"2015","unstructured":"Dembowy J, Adissu HA, Liu JC, Zacksenhaus E, Woodgett JR. Effect of glycogen synthase kinase-3 inactivation on mouse mammary gland development and oncogenesis. Oncogene. 2015;34(27):3514\u201326.","journal-title":"Oncogene"},{"key":"1098_CR40","doi-asserted-by":"publisher","unstructured":"Cormier KW, Woodgett JR. Recent advances in understanding the cellular roles of GSK-3. F1000Res. 2017;6. \n                    https:\/\/doi.org\/10.12688\/f1000research.10557.1\n                    \n                  .","DOI":"10.12688\/f1000research.10557.1"},{"issue":"11","key":"1098_CR41","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1038\/onc.2016.304","volume":"36","author":"T Zhan","year":"2017","unstructured":"Zhan T, Rindtorff N, Boutros M. Wnt signaling in cancer. Oncogene. 2017;36(11):1461\u201373.","journal-title":"Oncogene"},{"key":"1098_CR42","doi-asserted-by":"publisher","first-page":"460","DOI":"10.3389\/fimmu.2016.00460","volume":"7","author":"A Suryawanshi","year":"2016","unstructured":"Suryawanshi A, Tadagavadi RK, Swafford D, Manicassamy S. Modulation of inflammatory responses by Wnt\/beta-catenin signaling in dendritic cells: a novel immunotherapy target for autoimmunity and cancer. Front Immunol. 2016;7:460.","journal-title":"Front Immunol"},{"issue":"7","key":"1098_CR43","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1016\/j.cell.2012.11.024","volume":"151","author":"V Luga","year":"2012","unstructured":"Luga V, Zhang L, Viloria-Petit AM, Ogunjimi AA, Inanlou MR, Chiu E, Buchanan M, Hosein AN, Basik M, Wrana JL. Exosomes mediate stromal mobilization of autocrine Wnt-PCP signaling in breast cancer cell migration. Cell. 2012;151(7):1542\u201356.","journal-title":"Cell"},{"key":"1098_CR44","first-page":"378","volume":"7","author":"B Ma","year":"2016","unstructured":"Ma B, Hottiger MO. Crosstalk between Wnt\/beta-catenin and NF-kappaB signaling pathway during inflammation. Front Immunol. 2016;7:378.","journal-title":"Front Immunol"},{"issue":"7494","key":"1098_CR45","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/nature13187","volume":"508","author":"AS Cleary","year":"2014","unstructured":"Cleary AS, Leonard TL, Gestl SA, Gunther EJ. Tumour cell heterogeneity maintained by cooperating subclones in Wnt-driven mammary cancers. Nature. 2014;508(7494):113\u20137.","journal-title":"Nature"},{"issue":"3","key":"1098_CR46","first-page":"587","volume":"40","author":"M Katoh","year":"2017","unstructured":"Katoh M, Katoh M. Molecular genetics and targeted therapy of WNT-related human diseases (review). Int J Mol Med. 2017;40(3):587\u2013606.","journal-title":"Int J Mol Med"},{"issue":"11","key":"1098_CR47","doi-asserted-by":"publisher","first-page":"3965","DOI":"10.1083\/jcb.201712041","volume":"217","author":"KA White","year":"2018","unstructured":"White KA, Grillo-Hill BK, Esquivel M, Peralta J, Bui VN, Chire I, Barber DL. Beta-catenin is a pH sensor with decreased stability at higher intracellular pH. J Cell Biol. 2018;217(11):3965\u201376.","journal-title":"J Cell Biol"},{"issue":"9","key":"1098_CR48","doi-asserted-by":"publisher","first-page":"3296","DOI":"10.1172\/JCI41490","volume":"120","author":"Z Jiang","year":"2010","unstructured":"Jiang Z, Deng T, Jones R, Li H, Herschkowitz JI, Liu JC, Weigman VJ, Tsao MS, Lane TF, Perou CM, et al. Rb deletion in mouse mammary progenitors induces luminal-B or basal-like\/EMT tumor subtypes depending on p53 status. J Clin Invest. 2010;120(9):3296\u2013309.","journal-title":"J Clin Invest"},{"issue":"10","key":"1098_CR49","doi-asserted-by":"publisher","first-page":"3739","DOI":"10.1172\/JCI81568","volume":"126","author":"RA Jones","year":"2016","unstructured":"Jones RA, Robinson TJ, Liu JC, Shrestha M, Voisin V, Ju Y, Chung PE, Pellecchia G, Fell VL, Bae S, et al. RB1 deficiency in triple-negative breast cancer induces mitochondrial protein translation. J Clin Invest. 2016;126(10):3739\u201357.","journal-title":"J Clin Invest"},{"issue":"1","key":"1098_CR50","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s13058-015-0668-y","volume":"18","author":"S Wang","year":"2016","unstructured":"Wang S, Liu JC, Kim D, Datti A, Zacksenhaus E. Targeted Pten deletion plus p53-R270H mutation in mouse mammary epithelium induces aggressive claudin-low and basal-like breast cancer. Breast Cancer Res. 2016;18(1):9.","journal-title":"Breast Cancer Res"},{"issue":"27","key":"1098_CR51","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.1056\/NEJMoa041588","volume":"351","author":"S Paik","year":"2004","unstructured":"Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351(27):2817\u201326.","journal-title":"N Engl J Med"},{"issue":"15","key":"1098_CR52","doi-asserted-by":"publisher","first-page":"5832","DOI":"10.1073\/pnas.1201105109","volume":"109","author":"JC Liu","year":"2012","unstructured":"Liu JC, Voisin V, Bader GD, Deng T, Pusztai L, Symmans WF, Esteva FJ, Egan SE, Zacksenhaus E. Seventeen-gene signature from enriched Her2\/Neu mammary tumor-initiating cells predicts clinical outcome for human HER2+:ERalpha- breast cancer. Proc Natl Acad Sci U S A. 2012;109(15):5832\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"1098_CR53","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1038\/nrc1997","volume":"6","author":"GA Calin","year":"2006","unstructured":"Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006;6(11):857\u201366.","journal-title":"Nat Rev Cancer"}],"container-title":["Breast Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-019-1098-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13058-019-1098-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-019-1098-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,30]],"date-time":"2020-01-30T19:11:59Z","timestamp":1580411519000},"score":1,"resource":{"primary":{"URL":"https:\/\/breast-cancer-research.biomedcentral.com\/articles\/10.1186\/s13058-019-1098-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,31]]},"references-count":53,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1098"],"URL":"https:\/\/doi.org\/10.1186\/s13058-019-1098-z","relation":{},"ISSN":["1465-542X"],"issn-type":[{"value":"1465-542X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,31]]},"assertion":[{"value":"20 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"18"}}